These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26768633)

  • 1. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.
    Gudowska M; Wojtowicz E; Cylwik B; Gruszewska E; Chrostek L
    Adv Clin Exp Med; 2015; 24(5):823-7. PubMed ID: 26768633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.
    Gruszewska E; Gudowska M; Wojtowicz E; Cylwik B; Szmitkowski M; Chrostek L
    Clin Lab; 2015; 61(11):1769-74. PubMed ID: 26732004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The diagnostic value of non-invasive biochemical biomarkers in alcohol abuse].
    Supronowicz Ł; Wójtowicz E; Cylwik B; Gruszewska E; Chrostek L
    Pol Merkur Lekarski; 2013 Sep; 35(207):148-50. PubMed ID: 24224451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
    Bril F; McPhaul MJ; Caulfield MP; Castille JM; Poynard T; Soldevila-Pico C; Clark VC; Firpi-Morell RJ; Lai J; Cusi K
    J Investig Med; 2019 Feb; 67(2):303-311. PubMed ID: 30309884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease.
    Lardi LL; Lul RM; Port GZ; Coral GP; Peres A; Dornelles GP; Branco F; Fernandes S; Leães CG; Mattos AA; Buss C; Tovo CV
    Minerva Gastroenterol (Torino); 2022 Mar; 68(1):85-90. PubMed ID: 32700499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
    Munteanu M; Tiniakos D; Anstee Q; Charlotte F; Marchesini G; Bugianesi E; Trauner M; Romero Gomez M; Oliveira C; Day C; Dufour JF; Bellentani S; Ngo Y; Traussnig S; Perazzo H; Deckmyn O; Bedossa P; Ratziu V; Poynard T;
    Aliment Pharmacol Ther; 2016 Oct; 44(8):877-89. PubMed ID: 27549244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver steatosis associated with chronic hepatitis C.
    Irimia E; Mogoantă L; Predescu IO; Efrem IC; Stănescu C; Streba LA; Georgescu AM
    Rom J Morphol Embryol; 2014; 55(2):351-6. PubMed ID: 24969985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum IgA levels and IgA/IgG ratio in Alcoholic Liver Disease.
    BhatB NM
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of ¹³C-methacetin breath test for the non-invasive evaluation of nonalcoholic fatty liver disease.
    Fierbinteanu-Braticevici C; Plesca DA; Tribus L; Panaitescu E; Braticevici B
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):149-56. PubMed ID: 23799213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis.
    Cengiz M; Ozenirler S; Elbeg S
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1190-6. PubMed ID: 25684563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
    Perazzo H; Munteanu M; Ngo Y; Lebray P; Seurat N; Rutka F; Couteau M; Jacqueminet S; Giral P; Monneret D; Imbert-Bismut F; Ratziu V; Hartemann-Huertier A; Housset C; Poynard T;
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1081-93. PubMed ID: 25186086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravoxel Incoherent Motion Diffusion Weighted MR Imaging at 3.0 T: Assessment of Steatohepatitis and Fibrosis Compared with Liver Biopsy in Type 2 Diabetic Patients.
    Parente DB; Paiva FF; Oliveira Neto JA; Machado-Silva L; Figueiredo FA; Lanzoni V; Campos CF; do Brasil PE; Gomes Mde B; Perez Rde M; Rodrigues RS
    PLoS One; 2015; 10(5):e0125653. PubMed ID: 25961735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity.
    Fagan KJ; Pretorius CJ; Horsfall LU; Irvine KM; Wilgen U; Choi K; Fletcher LM; Tate J; Melino M; Nusrat S; Miller GC; Clouston AD; Ballard E; O'Rourke P; Lampe G; Ungerer JP; Powell EE
    Liver Int; 2015 Jun; 35(6):1673-81. PubMed ID: 25495373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.
    Lombardi R; Buzzetti E; Roccarina D; Tsochatzis EA
    World J Gastroenterol; 2015 Oct; 21(39):11044-52. PubMed ID: 26494961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procoagulant imbalance in patients with non-alcoholic fatty liver disease.
    Tripodi A; Fracanzani AL; Primignani M; Chantarangkul V; Clerici M; Mannucci PM; Peyvandi F; Bertelli C; Valenti L; Fargion S
    J Hepatol; 2014 Jul; 61(1):148-54. PubMed ID: 24657400
    [TBL] [Abstract][Full Text] [Related]  

  • 19.  High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients.
    Arab JP; Barrera F; Gallego C; Valderas JP; Uribe S; Tejos C; Serrano C; Serrano C; Huete Á; Liberona J; Labbé P; Quiroga T; Benítez C; Irarrázaval P; Riquelme A; Arrese M
    Ann Hepatol; 2016; 15(5):721-8. PubMed ID: 27493111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Assessment in Patients with Ataxia-Telangiectasia: Transient Elastography Detects Early Stages of Steatosis and Fibrosis.
    Donath H; Wölke S; Knop V; Heß U; Duecker RP; Trischler J; Poynard T; Schubert R; Zielen S
    Can J Gastroenterol Hepatol; 2023; 2023():2877350. PubMed ID: 36941982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.